Safety study pushes back phase 3 trial of Newron’s schizophrenia drugSwitzerland’s neurology specialist Newron must hold off starting a phase 3 study of its schizophrenia drug evenamide to Share XSafety study pushes back phase 3 trial of Newron’s schizophrenia drughttps://pharmaphorum.com/news/safety-trial-pushes-back-phase-3-trial-of-newrons-schizophrenia-drug/
Newron’s shares dive after rare disease drug failureNewron’s share price has collapsed after the biotech axed development of its drug sarizotan for the rare genetic brain disorder Rett Syndrome following the failure of a key trial. Share XNewron’s shares dive after rare disease drug failurehttps://pharmaphorum.com/news/newrons-shares-dive-after-rare-disease-drug-failure/
Newron plots phase 3 trial of schizophrenia drug after safety scareNewron Pharmaceuticals has clearance to press ahead with phase 3 development of its schizophrenia drug Evenamide after the Share XNewron plots phase 3 trial of schizophrenia drug after safety scarehttps://pharmaphorum.com/news/newron-plots-phase-3-trial-of-schizophrenia-drug-after-safety-scare/
Newron faces delay to would-be schizophrenia blockbusterNewron has been forced to delay the start of a pivotal trial of its schizophrenia candidate evenamide – Share XNewron faces delay to would-be schizophrenia blockbusterhttps://pharmaphorum.com/news/newron-faces-delay-to-would-be-schizophrenia-blockbuster/
Newron to re-file Parkinson’s drug in USRegulator drops demand for further clinical trials. Share XNewron to re-file Parkinson’s drug in UShttps://pharmaphorum.com/news/newron-refile-parkinsons-drug-us/
